THERAPY DOSSIER · th-88c2473350c9

Celastrol loaded in neutrophil membrane-coated PEG-PLGA nanoparticles (NNPs/CLT)

Drug · Celastrol, a quinone-methide triterpenoid (Tripterygium), here in neutrophil-membrane PEG-PLGA nanoparticles; not returned by ChEMBL name search.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: Celastrol, a quinone-methide triterpenoid (Tripterygium), here in neutrophil-membrane PEG-PLGA nanoparticles; not returned by ChEMBL name search.
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05494112 ↗NAunknown

A Sub-Chronic Evaluation of the Safety of Celastrol in Human Subjects

Safety

Enrolment: 35 · Results not recorded

NCT05413226 ↗NAunknown

Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility

Safety Issues

Enrolment: 5 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30753778 ↗2019Reported benefit

Inflammation-Targeted Delivery of Celastrol via Neutrophil Membrane-Coated Nanoparticles in the Management of Acute Pancreatitis.

RatOtherSprague-DawleyMale

Model: Acute pancreatitis

Neutrophil membrane-coated nanoparticles crossed the blood-pancreas barrier and accumulated selectively in inflamed pancreas. Compared with celastrol solution and uncoated nanoparticles, they significantly reduced serum amylase and pancreatic myeloperoxidase and lowered systemic toxicity of celastr…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…